Jadenu and Bleeding into the skin - a phase IV clinical study of FDA data
Summary:
Bleeding into the skin is reported as a side effect among people who take Jadenu (deferasirox), especially for people who are male, 50-59 old, also take Eltrombopag Olamine, and have Aplastic anemia.
The phase IV clinical study analyzes which people have Bleeding into the skin when taking Jadenu. It is created by eHealthMe based on reports of 4,173 people who have side effects when taking Jadenu from the FDA, and is updated regularly.
What is Jadenu?
Jadenu has active ingredients of deferasirox. eHealthMe is studying from 4,176 Jadenu users. Check the latest studies of Jadenu.
What is Bleeding into the skin?
Bleeding into the skin is found to be associated with 937 drugs and 1,908 conditions by eHealthMe. Check the latest studies of Bleeding into the skin.
4,173 people reported to have side effects when taking Jadenu.
Among them, 11 people (0.26%) have Bleeding into the skin.
Among these 11 people:
What is the gender of people who have Bleeding into the skin when taking Jadenu? *
- female: 27.27 %
- male: 72.73 %
What is the age of people who have Bleeding into the skin when taking Jadenu? *
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 81.82 %
- 60+: 18.18 %
What are other drugs people take besides Jadenu? *
- Eltrombopag Olamine: 4 people, 36.36%
- Ciclosporin: 1 person, 9.09%
What are other side effects people have besides Bleeding into the skin? *
- Thrombocytopenia (decrease of platelets in blood): 11 people, 100.00%
- Haemoglobin Decreased: 8 people, 72.73%
- Paleness (unusual lightness of skin colour): 8 people, 72.73%
- Otitis (ear infection): 5 people, 45.45%
- Disease Recurrence: 5 people, 45.45%
- Serum Ferritin Increased: 5 people, 45.45%
- Back Pain: 5 people, 45.45%
- Diarrhea: 5 people, 45.45%
- Rashes (redness): 5 people, 45.45%
- Haemorrhage (bleeding): 5 people, 45.45%
What are the existing conditions these people have? *
- Aplastic Anemia: 7 people, 63.64%
- Iron Overload: 2 people, 18.18%
* Approximation only. Some reports may have incomplete information.
Do you take Jadenu and have Bleeding into the skin?
- Check whether Bleeding into the skin is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Jadenu:
- Jadenu (4,176 reports)
Bleeding into the skin treatments and more:
- Bleeding into the skin (15,174 reports)
How severe was Bleeding into the skin and when was it recovered:
Expand to all the drugs that have ingredients of deferasirox:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Jadenu:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Bleeding into the skin:
- Bleeding into the skin (937 drugs)
Browse all the conditions that are associated with Bleeding into the skin:
- Bleeding into the skin (1,908 conditions)
Related publications that referenced our studies
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on deferasirox (the active ingredients of Jadenu) and Jadenu (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Losartan Potassium; Hydrochlorothiazide vs. Amlodipine Maleate; Benazepril Hydrochloride, side effect and effectiveness comparison - a second ago
- Drug interactions of Calcium Citrate and Coq10 - 17 seconds ago
- Could Pantoprazole cause Kidney Stones? - 19 seconds ago
- Drug interactions of Calcium Citrate and Avandia - 19 seconds ago
- Sonata vs. Xyrem, side effect and effectiveness comparison - 38 seconds ago
- Oxycodone Hydrochloride vs. Percodan, side effect and effectiveness comparison - 40 seconds ago
- Could Bystolic cause Influenza Like Illness? - 42 seconds ago
- Quinapril Hydrochloride vs. Enalaprilat, side effect and effectiveness comparison - 51 seconds ago
- Elavil vs. Wellbutrin Sr, side effect and effectiveness comparison - 59 seconds ago
- Could Caffeine cause Diabetes Mellitus Non-Insulin-Dependent? - a minute ago